Ignite Creation Date:
2025-12-24 @ 12:23 PM
Ignite Modification Date:
2025-12-27 @ 10:40 PM
Study NCT ID:
NCT00807261
Status:
UNKNOWN
Last Update Posted:
2008-12-12
First Post:
2008-12-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Sponsor:
Asan Medical Center
Organization:
Study Overview
Official Title:
Phaseâ…¡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional
Status:
UNKNOWN
Status Verified Date:
2008-12
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide
1. Primary endpoint: response rate
2. Secondary endpoint: progress-free survival, overall survival, safety
1. Primary endpoint: response rate
2. Secondary endpoint: progress-free survival, overall survival, safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: